Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab for recurrent glioblastoma – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Glioblastoma is a type of brain cancer that develops from cells that support nerve tissue. Glioblastoma is the most common type of brain cancer. After surgery or chemotherapy, this cancer often returns and most patients with glioblastoma do not survive for very long after their diagnosis.
Nivolumab is a new antibody drug for the treatment of glioblastoma and is delivered straight into the bloodstream via a drip. It may stimulate the immune system to attack cancer cells. Some studies have suggested nivolumab may be helpful for people whose first treatment has failed and whose disease has spread. Another, larger study is now running and is aiming to find out how well nivolumab works and that it is safe to use.
If nivolumab is licenced for use in the UK, it could be a new treatment option for patients with glioblastoma that may improve survival when current treatments have stopped working. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antineoplastic Agents; Glioblastoma; Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000399 Date abstract record published 04/03/2016 |